### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours por rosponso:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BELANOFF JOSEPH K													Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner							
	CEPT TH	irst) ERAPEUTICS ALTH DRIVE	(Middle)		3. Date of Earliest Transact 07/27/2006					saction (Month/Day/Year)						er (give title w)	е		r (specify v)	
(Street)	PARK C	A	94025 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	n-Deriv	ative	Sec	uritie	s Ac	quired	, Dis	sposed o	f, or I	Benef	iciall	y Own	ed				
		2. Transaction Date (Month/Day/Yea		Execution Date,		Transaction Disposed (Code (Instr. 5)		es Acquired (A) or Of (D) (Instr. 3, 4 and			nd Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	n: Direct or Indirect	7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount	(A) (D)	or Pr	ice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common	Stock														300	0,000		I	Custodian for a minor daughter <sup>(1)</sup>	
Common Stock													300	0,000		I	Custodian for minor son <sup>(1)</sup>			
Common	Common Stock 07/27/2				2006			<b>S</b> <sup>(2)</sup>		1,251	D		\$4	2,208,531			D			
Common	Stock			07/28/2	2006				<b>S</b> <sup>(2)</sup>		668	D	, ,	\$3.9	2,207,863 D					
Common	Stock			07/28/2	2006				<b>S</b> <sup>(2)</sup>		1,668	D	\$	3.85	2,206,195			D		
Common	Stock 07/31		07/31/2	2006				S <sup>(2)</sup>		2,000	D	\$	3.775	2,204,195		D				
		Ta	able II -								osed of, convertib				Owned					
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)		on Date, Day/Year)		nsaction de (Instr. 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Exercisable Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of Title Shares		r. 3	8. Price of Derivative Security (Instr. 5)  9. Numbe derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)		ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

#### **Explanation of Responses:**

- 1. The Reporting Person is the custodian for minor children and disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.
- 2. The sale on this Form 4 was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 15, 2004.

# Remarks:

s/s Fred Kurland, CFO of **Corcept Therapeutics** Incorporated attorney-in-fact

07/31/2006

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.